SK Bioscience Rewriting History, Will Stock Price Soar Despite Market Correction?

[Asia Economy Reporter Song Hwajeong] SK Bioscience, which has launched its initial public offering (IPO), is drawing attention as to whether it will inject vitality into the stock market, which is currently showing signs of adjustment, by creating a sensation.

According to the financial investment industry on the 9th, SK Bioscience is conducting a general public subscription for individual investors from today until the 10th.

SK Bioscience's offering price was set at 65,000 KRW, the top end of the desired price band (49,000 to 65,000 KRW). Applying this offering price, the company's valuation reaches 5 trillion KRW.

During the demand forecast for institutional investors held on the 4th and 5th, SK Bioscience recorded a competition rate of 1,275.47 to 1, the highest ever in the KOSPI market. Among the participating institutions, 1,406, or 96.04%, offered prices at or above the top end of the desired price band of 65,000 KRW. Institutions that committed to a lock-up period ranging from a minimum of 15 days to a maximum of 6 months accounted for 59.92% of the total application quantity.

The general public subscription starting today will be accepted by six securities firms: NH Investment & Securities, Korea Investment & Securities, Mirae Asset Daewoo, SK Securities, Samsung Securities, and Hana Financial Investment. The allocation for individual investors is 5,737,500 shares, which is 25% of the total offering volume. Of this, 50%, or 2,868,750 shares, will be allocated equally.

Given the record-breaking competition rate in the demand forecast, there is keen interest in how much subscription deposit will be gathered during the general subscription. Last year, Kakao Games attracted 5,855.43 billion KRW, setting a record high, and SK Biopharm drew 3,098.99 billion KRW.

Attention is also focused on the stock price trend after SK Bioscience's listing scheduled for the 18th. If SK Bioscience achieves the so-called 'ttasang'?where the opening price on the first day of listing is double the offering price and then surges to the upper limit?the stock price is expected to rise to 169,000 KRW. Amid the recent market adjustments, if SK Bioscience shows strong stock performance after listing, such as achieving ttasang, it is expected to inject vitality into the stock market.

This content was produced with the assistance of AI translation services.